JEADV clinical practice最新文献

{"title":"Cutaneous presentations of systemic sclerosis in skin of colour: A systematic review","authors":"Alicia Podwojniak,&nbsp;Isabella J. Tan,&nbsp;Aliza Leiter,&nbsp;Hira Ghani,&nbsp;Bernard A. Cohen","doi":"10.1002/jvc2.527","DOIUrl":"https://doi.org/10.1002/jvc2.527","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 <p>Systemic sclerosis (SSc), a rheumatologic autoimmune disease, can present diversely, especially in patients with skin of colour (SOC). Differences in clinical manifestations among SOC individuals compared to predominantly White populations require a comprehensive examination to optimize diagnosis and treatment. This systematic review aims to explore the differences in SSc manifestations among individuals with SOC, identifying variations in disease severity, clinical features and psychosocial impacts. A systematic review of the literature was conducted following PRISMA guidelines. Databases searched included PubMed, SCOPUS, Cochrane and Web of Science, focusing on studies published within the last 10 years. Nine studies were selected and qualitatively analysed due to the heterogeneity of study types. Key findings highlight significant variations in disease severity and cutaneous clinical features among SOC cohorts compared to predominantly White populations. Raynaud's phenomenon was prevalent across all ethnicities; however, SOC groups exhibited fewer hallmark features of scleroderma, such as telangiectasias, calcinosis and digital swelling, which complicates diagnosis. SOC individuals showed a higher propensity for severe pulmonary complications and increased mortality rates. Atypical cutaneous presentations in SOC were associated with disease progression. Psychosocial impacts were more pronounced in SOC individuals, with greater awareness and dissatisfaction over cutaneous symptoms. Recognizing the atypical presentations of SSc in SOC is critical for early diagnosis and optimizing patient outcomes. The study underscores the need for further research to determine if observed differences are due to variations in prevalence, genetic factors or insufficient training in recognizing cutaneous manifestations in SOC. Enhanced awareness and targeted training for healthcare providers are essential to address these diagnostic challenges and improve care for SOC patients with SSc.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"3 5","pages":"1420-1429"},"PeriodicalIF":0.0,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.527","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142762718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Posttransplantation course after allogeneic stem cell transplantation in a patient with advanced mycosis fungoides—Balancing relapse and rejection","authors":"Inga Hansen-Abeck,&nbsp;Chiara L. Blomen,&nbsp;Finn Abeck,&nbsp;Leopold Torster,&nbsp;Stefan W. Schneider,&nbsp;Nina Booken","doi":"10.1002/jvc2.514","DOIUrl":"https://doi.org/10.1002/jvc2.514","url":null,"abstract":"<p>Treatment of advanced cutaneous T-cell lymphoma (CTCL) can be challenging. To date, the only potentially curative treatment option for advanced CTCL is allogeneic hematopoietic stem cell transplantation. We report on a patient with mycosis fungoides who received allogeneic hematopoietic stem cell transplantation due to rapid progression of the disease. Eight months after transplantation, relapse as well as chronic graft-versus-host disease occurred. Therefore, we initiated different treatment modalities, including bexarotene, extracorporeal photopheresis, topical treatment as well as the Janus-kinase-inhibitor Ruxolitinib. Even though the patient experienced high morbidity due to the allogeneic hematopoietic stem cell transplantation, 3 years after he is still alive and reports good health-related quality of life. With this case, we aim to demonstrate that the posttransplant course can be difficult, balancing between relapse and graft-versus-host disease. Nevertheless, patients can benefit in terms of survival and their health-related quality of life. Therefore, allogeneic hematopoietic stem cell transplantation should be considered as a treatment option, especially for patients with advanced CTCL and poor prognosis.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"3 5","pages":"1660-1664"},"PeriodicalIF":0.0,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.514","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142762755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lifestyle, medication use, and age considerations with acne vulgaris: A prospective study","authors":"Ashley M. Snyder,&nbsp;Caroline J. Stone,&nbsp;Nicole Ufkes,&nbsp;Tom Greene,&nbsp;Mary C. Playdon,&nbsp;Maureen A. Murtaugh,&nbsp;Megan E. Vanneman,&nbsp;Aaron M. Secrest","doi":"10.1002/jvc2.521","DOIUrl":"https://doi.org/10.1002/jvc2.521","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lifestyle has been associated with acne, but few studies assess how the relationship changes over time. Observational studies often overlook the effects of acne medication use and participant age in relationships with lifestyle-related factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To describe relationships between lifestyle-related factors, medication use, and age in adolescent and young adult acne patients and acne-free controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective study recruited 12- to 24-year-olds with or without acne at baseline. Surveys were electronically administered at enrolment and again 6 weeks later. Analyses were conducted on all participants who had complete baseline data (<i>N</i> = 190) and participants who had complete baseline and follow-up data (<i>N</i> = 61).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 190 participants who completed the baseline survey, ages ranged from 12 to 24 years, but acne cases were concentrated in the middle of this range while controls had comparably more participants with ages towards the extremes. Among 61 participants who completed both baseline and follow-up surveys, no participants indicated worse acne over the 6 weeks, and most acne cases believed their acne improved (<i>n</i> = 25 [69.4%]). Acne cases who used medication daily (<i>N</i> = 24) saw improved emotion-related quality of life between the two assessments (mean ± standard deviation: 43.4 ± 24.4 to 29.1 ± 23.7; <i>p</i> &lt; 0.001). Among acne cases who used medication daily, average fruit or vegetable consumption increased from 2.4 ± 2.0 to 3.0 ± 2.9 times per day over the preceding 7 days (<i>p</i> = 0.02). Among acne cases who believed their acne improved over the 6 weeks post-dermatology visit (<i>N</i> = 25), average days of skin picking over the previous 7 days declined between assessments (3.9 ± 2.4 to 2.4 ± 1.9 days; <i>p</i> = 0.003).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Medication use and age differences should be considered when designing future studies on acne and lifestyle-related factors.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 1","pages":"82-94"},"PeriodicalIF":0.0,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.521","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143530306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of recalcitrant follicular lichen planus (lichen planopilaris) with the topical JAK 1/2 inhibitor ruxolitinib","authors":"Tanja Fetter,&nbsp;Dagmar Wilsmann-Theis,&nbsp;Luka de Vos-Hillebrand,&nbsp;Natalija Novak,&nbsp;Joerg Wenzel","doi":"10.1002/jvc2.515","DOIUrl":"https://doi.org/10.1002/jvc2.515","url":null,"abstract":"<p>We report the successful treatment of a patient with refractory follicular lichen planus (LP) with topical ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, which resulted in significant improvement of lesional skin within 1 month of daily use.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 1","pages":"220-223"},"PeriodicalIF":0.0,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.515","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143530789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab-related ocular surface disorders in a paediatric cohort with atopic dermatitis, treated in a tertiary paediatric hospital in London","authors":"Anjali Rampersad,&nbsp;Karolina Gholam,&nbsp;Lea Solman,&nbsp;Natalia Cartledge,&nbsp;Sri Gore,&nbsp;Gabriela Petrof","doi":"10.1002/jvc2.528","DOIUrl":"https://doi.org/10.1002/jvc2.528","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Dupilumab is the first human monoclonal antibody approved for the treatment of moderate–severe atopic dermatitis (AD) in children from 6 years of age. Real-world studies reviewing dupilumab-related ocular surface disorders (DROSD) in the paediatric population are needed to detail ophthalmological findings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This cross-sectional observational study aimed to review the incidence, features, and ophthalmological findings of DROSD in a real-world paediatric cohort, treated with dupilumab for AD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Pharmacy and electronic medical records were used to identify all patients prescribed dupilumab for AD from April 2019 to July 2022. Data, including demographics, ocular signs and symptoms, severity and treatments, were collected and analysed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified 46 patients, with a median age of treatment initiation of 12 years (range 9–14 years). Twelve patients (26.1%) developed DROSD. Mean time to development of DROSD was 4.1 months (±2.4 months, 95% confidence interval). Two patients (16.7%) with DROSD had severe eye findings including peripheral corneal opacification, one of which had reported only asymptomatic red eyes. Ocular signs included 91.7% (11/12) bulbar conjunctival injection, 41.7% (5/12) follicle involvement (limbal or forniceal), 25% (3/12) diffuse tarsal-conjunctival thickening, 16.7% (2/12) featureless thickening, 16.7% (2/12) peripheral corneal opacification, 8.3% (1/12) cicatrisation and 8.3% (1/12) periorbital skin changes. No patients ceased treatment due to DROSD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study had a higher incidence of DROSD, compared to other real-world paediatric studies but had a similar incidence to real-world adult studies. Patient-reported eye symptoms did not always correlate to severity of DROSD. Larger paediatric studies looking at the incidence and long-term outcome of DROSD are needed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"3 5","pages":"1558-1563"},"PeriodicalIF":0.0,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.528","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142762639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) reported in association with HIV antiretroviral therapy: An analysis of the FDA Adverse Event Reporting System","authors":"Bianca E. Ituarte,&nbsp;Mitchell A. Taylor,&nbsp;Erin X. Wei,&nbsp;Jennifer Adams","doi":"10.1002/jvc2.513","DOIUrl":"https://doi.org/10.1002/jvc2.513","url":null,"abstract":"&lt;p&gt;Antiretroviral medications used to treat and prevent human immunodeficiency virus (HIV) are the cornerstone in management and should be initiated as early as possible.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; These medications are widely regarded as efficacious, with benefits outweighing potential risks and contributing to longer, healthier lives for patients. Previous literature has described nevirapine and raltegravir, two commonly prescribed medications, as associated with the development of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS);&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt; however, little is known regarding reports of cutaneous drug eruptions among other antiretrovirals. This study seeks to provide a classification of reported events of DRESS in relation to the use of antiretrovirals for HIV prevention and treatment.&lt;/p&gt;&lt;p&gt;The FDA Adverse Event Reporting System (FAERS) Public Dashboard was used to extract all available data through 31 December 2023 for the analysis of reports of DRESS in relation to 40 different HIV antiretroviral medications. These medications were categorized into seven groups: combination antiretrovirals (cARTs), nucleoside reverse transcriptase inhibitors (NRTIs), non-NRTIs (NNRTIs), entry inhibitors (EIs), protease inhibitors (PIs), integrase inhibitors (INSTIs), and boosting agents (BAs). A full description of each medication included can be found in Table 1. To ensure broad data collection, both brand and generic names were included for each unique medication. The frequencies of both DRESS and total cutaneous-specific adverse events were recorded in Figure 1.&lt;/p&gt;&lt;p&gt;Among the 40 unique antiretroviral medications analysed, there were 30,353 cutaneous-specific adverse events. Among these, 1295 (4.3%) were cases of DRESS. Six relatively new medications (with brand name—drug class) that had no reported cases at the time of data collection were as follows: dolutegravir/lamivudine (Dovato—cART), doravirine/lamivudine/tenofovir disoproxil (Delstrigo—cART), darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza—cART), atazanavir/cobicistat (Evotaz—PI), nelfinavir (Viracept—PI), and ibalizumab-uiyk (Trogarzo—EI). Individual antiretrovirals most reported in association with DRESS were raltegravir (Isentriss—INSTI) (15.0% of DRESS cases, &lt;i&gt;n&lt;/i&gt; = 194), ritonavir (Norvir—BA) (10.5%, &lt;i&gt;n&lt;/i&gt; = 136), atazanavir (Reyataz—PI) (10.2%, &lt;i&gt;n&lt;/i&gt; = 132), lopinavir/ritonavir (Kaletra—PI) (8.3%, &lt;i&gt;n&lt;/i&gt; = 107), and emtricitabine/tenofovir (Truvada—cART) (7.8%, &lt;i&gt;n&lt;/i&gt; = 101). Nevirapine (Viramune—NNRTI) had 71 reported cases (5.5%). Among medication classes, the most reported in association with DRESS was PI (27.8%, &lt;i&gt;n&lt;/i&gt; = 359), followed by cART (20.3%, &lt;i&gt;n&lt;/i&gt; = 263) and NRTIs (12.4%, &lt;i&gt;n&lt;/i&gt; = 160). The newest class of antiretroviral therapy, the EIs, was the lowest reported class, with 10 total cases at the time of data collection.&lt;/p&gt;&lt;p&gt;This study provides a collection of reported cases of DRESS associated with antiretrov","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"3 5","pages":"1701-1704"},"PeriodicalIF":0.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.513","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142762792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysing referral patterns from a primary dermatological clinic to other medical institutions for further care: A survey on patients with certain skin diseases in Japan","authors":"Daisuke Ueo,&nbsp;Takashi Sakai,&nbsp;Erika Ochiai,&nbsp;Jun Sese,&nbsp;Yutaka Hatano","doi":"10.1002/jvc2.517","DOIUrl":"https://doi.org/10.1002/jvc2.517","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Various skin diseases exist; some require specialist treatment. Consequently, patients with these conditions are often referred from primary dermatological clinics to other medical institutions for further secondary or tertiary care. However, it has yet to be fully evaluated at primary dermatological clinics which skin conditions necessitate such referrals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aims to identify skin conditions that often require further care when treated at a primary dermatological clinic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study enroled 14,306 patients who had visited the Ueo Dermatology Clinic (a primary dermatological clinic in Saiki City, Oita prefecture, Japan) from 1 January 2020 to 31 December 2022. The following clinical information was examined: the primary disease, age, sex, whether referrals (general or emergency) were made after the clinic visit or not, and the reasons for the referrals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>'Eczema and dermatitis' was the most frequent category in the clinic, although the referral rates for this category were not exceptionally high compared to other categories. A large number of emergency referrals was observed for 'Viral infections (herpes zoster),' 'Drug-induced skin reactions,' and 'Bacterial infections (cellulitis)'; a large number of general referrals was observed for 'Malignant skin tumours and melanomas' and 'Benign skin tumours.' Although low numbers, the rates for general and emergency referrals were high in the categories of 'Blistering Diseases,' 'Connective Tissue Diseases,' and 'Vasculitis, Purpura, and Other Vascular Diseases.' In an analysis of the reasons for the referrals, the following reasons ranked highest: requirement for high-level medical treatment, surgical operation, or hospitalisation, and consultation with doctors in departments other than dermatology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study identified several skin conditions often requiring additional care when treated at a primary dermatological clinic. Based on these findings, seamless cooperation between primary clinics and specialised medical institutions is anticipated.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 1","pages":"181-187"},"PeriodicalIF":0.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.517","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143530581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma","authors":"Tomomichi Shimizu,&nbsp;Nobuhiro Takahashi,&nbsp;Aya Okaniwa,&nbsp;Reiko Saito,&nbsp;Akio Kondoh,&nbsp;Fumikazu Yamazaki,&nbsp;Shunsuke Nagase,&nbsp;Naoya Nakamura,&nbsp;Kazuya Takeuchi,&nbsp;Tomotaka Mabuchi","doi":"10.1002/jvc2.519","DOIUrl":"https://doi.org/10.1002/jvc2.519","url":null,"abstract":"<p>A 65-year-old Japanese woman with primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma, a rare type with a poor prognosis, is presented. Oral bexarotene and vorinostat were ineffective, and hematopoietic stem cell transplantation was scheduled. We stress that primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma should be treated with bone marrow transplantation when available.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 1","pages":"224-228"},"PeriodicalIF":0.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.519","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143530580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virtual reality for improvement of patient experience during endovenous laser ablation for venous insufficiency","authors":"Mitchell A. Taylor,&nbsp;Katherine Plampton,&nbsp;Robin High,&nbsp;Ashley Wysong,&nbsp;Adam Sutton","doi":"10.1002/jvc2.524","DOIUrl":"https://doi.org/10.1002/jvc2.524","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic venous insufficiency is a commonly underdiagnosed, highly prevalent disease that causes significant patient morbidity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The aim of this study is to assess the utility of virtual reality (VR) during outpatient endovenous laser ablation procedures with the goal of reducing patient-reported anxiety or pain. The authors also sought to examine the effects on patient-reported overall satisfaction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients completed a two-part survey interrupted by an immersive VR experience. Differences in the pre- and post-VR surveys were compared using a chi-square test. The pain scores were compared using a <i>t</i>-test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The pre-VR mean Beck Anxiety Inventory score was 1.41, decreasing post-VR to 1.33 (a reduction of 0.08; <i>p</i> &lt; 0.001). There were statistically significant differences for 3 questions including 'Are you currently feeling fear of the worst happening' (<i>p</i> = 0.04), 'Are you currently feeling nervous' (<i>p</i> &lt; 0.001), and 'Are you currently feeling scared' (<i>p</i> = 0.04).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Overall, our study demonstrates that a VR experience during endovenous laser ablations significantly improved measures of anxiety and patient satisfaction.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 1","pages":"188-194"},"PeriodicalIF":0.0,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.524","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143530485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To assess the attitudes of Irish patients attending a pigmented lesion clinic and healthcare staff employed in an academic hospital to biobanking, a quantitative study","authors":"Stephanie Bowe,&nbsp;Claire Quigley,&nbsp;Liana Victory,&nbsp;Eoin Storan","doi":"10.1002/jvc2.501","DOIUrl":"https://doi.org/10.1002/jvc2.501","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A Biobank is a collection of biospecimens or biological samples and corresponding patient data points which are used for the purposes of medical research. Patient participation and support is imperative to biobank research.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We aim to quantitatively assess the attitudes of Irish patients attending a pigmented lesion clinic (PLC) in an Irish dermatology centre and staff working at an academic teaching hospital, to biobanking.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A questionnaire was distributed to Healthcare staff working in an Academic Hospital and members of the Irish Association of Dermatology via their hospital email address. Patients who attended PLC January–April 2023, and patients previously diagnosed with melanoma January 2019–January 2021 were asked to complete the questionnaire. Respondents from a market research company, Bounce insights, was sent a modified questionnaire via a survey.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In total there were 426 respondents of ages; 16–&lt;18 years = 31 (7%), 18–35 years = 105 (25%), 36–65 years = 191 (45%) and &gt;65 years = 99 (23%). There were 166 (39%) males and 260 (61%) females. Of the 426 total respondents there were 180 (42%) previous healthcare workers. The number of total participants who were aware of biobanks was 130 (31%), no = 283 (66%), not sure = 13 (3%). Over 20% (84) of participants had donated a biospecimen previously. Healthcare workers reported a positive response in 84% (102) but only 46% (72) of the Bounce marketing respondents felt similarly (&lt;i&gt;p&lt;/i&gt; = &lt;0.001). Over 60% of healthcare staff, 16% of all patients and 21% of the Bounce marketing group were aware of Biobanks. In total 83% (352) of all respondents were willing to donate a biospecimen following a medical procedure but 78% (331) were willing to donate an additional blood sample and that number fell to 57% (242) when asked if they would donate an additional tissue sample purely for the purposes of research. The number who would encourage a family member to donate a biospecimen was; yes = 241 (56.5%), no = 41 (9.6%) and not sure = 144 (34%). Interestingly age was related to individuals' initial impression of biobanks (&lt;i&gt;X&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; (6, &lt;i&gt;N&lt;/i&gt; = 426) = 32, &lt;i&gt;p&lt;/i&gt; = &lt;0.001), to a willingness to donate a biospecimen (&lt;i&gt;p&lt;/i&gt; = &lt;0.039) and to a desire to be informed if their specimen was disposed of (&lt;i&gt;p&lt;/i&gt; = &lt;0.001).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 ","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"3 5","pages":"1587-1595"},"PeriodicalIF":0.0,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.501","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142762340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}